Damora Therapeutics (DMRA) Cash & Equivalents Growth (3y) (2022 - 2026)

Damora Therapeutics (DMRA) Cash & Equivalents Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -8.88%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 47.78%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Damora Therapeutics 1.01 Bn 807.71 Mn - 100.61%

Historic Data

Download Data
DateValue
Mar 31, 2026 100.61%
Dec 31, 2025 98.81%
Sep 30, 2025 -49.97%
Jun 30, 2025 -49.15%
Mar 31, 2025 -49.09%
Dec 31, 2024 -39.04%
Sep 30, 2024 -33.22%
Jun 30, 2024 -42.97%
Mar 31, 2024 -34.27%
Dec 31, 2023 -46.32%
Sep 30, 2023 -22.35%
Jun 30, 2023 -13.80%
Mar 31, 2023 -16.32%
Sep 30, 2022 60.48%